Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Birth order

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    382 result(s) found for: Birth order. Displaying page 7 of 20.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2011-003412-23 Sponsor Protocol Number: V00251IV2024A Start Date*: 2012-01-25
    Sponsor Name:Pierre Fabre Médicament - IRPF
    Full Title: EFFECT OF V0251 IN ACUTE VERTIGO. A RANDOMISED DOUBLE-BLIND PLACEBO CONTROLLED STUDY.
    Medical condition: V0251 is a new antivertiginous agent which is being developed for the treatment of symptomatic vertiginous crisis.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10013993 - Ear and labyrinth disorders 10047340 Vertigo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) ES (Completed) DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-005621-55 Sponsor Protocol Number: 99010206E Start Date*: 2006-06-14
    Sponsor Name:Zeria Pharmaceutical Co., Ltd.
    Full Title: Z-338:A Phase IIb, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety in Subjects with Functional Dyspepsia
    Medical condition: Functional Dyspepsia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10064536 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (Completed) BE (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000812-29 Sponsor Protocol Number: AMB 320 Start Date*: 2005-09-21
    Sponsor Name:Myogen, Inc.
    Full Title: Ambrisentan in PAH - A Phase III, Randomised, Double- Blind, Placebo- Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    7.0 10037400 low
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) AT (Completed) BE (Completed) IT (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000365-37 Sponsor Protocol Number: MIN-003-1806 Start Date*: 2019-06-04
    Sponsor Name:Lipopharma Therapeutics
    Full Title: A randomized, double-blind, placebo-controlled adjuvant trial in newly diagnosed primary glioblastoma subjects to assess the efficacy and safety of 2-hydroxyoleic acid (2-OHOA) in combination with ...
    Medical condition: Newly diagnosed primary glioblastoma multiforme (ndGBM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-003226-19 Sponsor Protocol Number: MS-LAQ-301 Start Date*: 2007-09-05
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: Study Title: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laq...
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) GB (Completed) FR (Completed) CZ (Completed) LV (Completed) AT (Completed) LT (Completed) ES (Completed) EE (Completed) PT (Prematurely Ended) SE (Completed) IT (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001549-41 Sponsor Protocol Number: 0881A3-402-WW Start Date*: 2005-11-25
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc
    Full Title: A Randomised, Double-Blind Study Comparing the Safety and Efficacy of Etanercept with Sulphasalazine in Subjects with Ankylosing Spondylitis
    Medical condition: Subjects with Ankylosing Spondylitis (AS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) FI (Completed) AT (Completed) DE (Completed) GB (Completed) DK (Completed) SE (Completed) PT (Completed) IE (Completed) GR (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000929-40 Sponsor Protocol Number: ET743-SAR-3007 Start Date*: 2016-08-09
    Sponsor Name:Janssen Research & Development, LLC
    Full Title: A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma
    Medical condition: advanced L-sarcoma (liposarcoma or leiomyosarcoma)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024627 Liposarcoma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024189 Leiomyosarcoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-007027-40 Sponsor Protocol Number: 0205-1isni07 / 001.112 Start Date*: 2008-03-07
    Sponsor Name:Centre Georges-François Leclerc
    Full Title: A Multicenter open-label, phase I/II dose escalation study of oral lapatinib in combination with docetaxel in patients with HER2 positive advanced or metastatic breast cancer
    Medical condition: HER 2 positive advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005594-21 Sponsor Protocol Number: ADP-04511 Start Date*: 2016-08-18
    Sponsor Name:Adaptimmune LLC
    Full Title: A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patients with Synovial Sarcoma
    Medical condition: Unresectable, metastatic or recurrent synovial sarcomas
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001581-20 Sponsor Protocol Number: IRRB/72/14 Start Date*: 2018-02-08
    Sponsor Name:ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE - ISMETT
    Full Title: THE ADDITION OF SIMVASTATIN ADMINISTRATION TO COLD STORAGE SOLUTION OF EXPLANTED WHOLE LIVER GRAFTS FOR FACING ISCHEMIA/REPERFUSION INJURY IN AN AREA WITH LOW RATE OF DECEASED DONATION. A MONOCENT...
    Medical condition: ISCHEMIC REPERFUSION INJURY AFTER LIVER TRANSPLANTATION: HEPATIC ISCHEMIA AND REPERFUSION INJURY REPRESENTS THE MAIN UNDERLYING MECHANISM FOR GRAFT DYSFUNCTION, AND FAILURE, POST-TRANSPLANTATION. H...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10047065 - Vascular disorders 10063837 Reperfusion injury PT
    20.0 10042613 - Surgical and medical procedures 10024714 Liver transplant PT
    20.1 10022117 - Injury, poisoning and procedural complications 10058060 Graft complication PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001483-38 Sponsor Protocol Number: BAY1163877/19131 Start Date*: 2019-09-02
    Sponsor Name:Bayer AG
    Full Title: An international, multicenter, Phase 1b/2 study of rogaratinib (BAY 1163877) in combination with atezolizumab as first-line treatment in cisplatin-ineligible patients with FGFR-positive locally adv...
    Medical condition: FGFR-positive locally advanced or metastatic urothelial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001783-34 Sponsor Protocol Number: MK-0517-044 Start Date*: 2015-08-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A phase III, randomized, placebo-controlled clinical trial to study the efficacy and safety of MK-0517/fosaprepitant and ondansetron versus ondansetron for the prevention of chemotherapy-induced na...
    Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with emetogenic chemotherapy
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed) ES (Completed) LT (Completed) FI (Completed) PT (Completed) EE (Completed) HU (Completed) GB (Completed) NL (Completed) GR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-012123-28 Sponsor Protocol Number: F13640 CP 201 Start Date*: 2009-07-15
    Sponsor Name:Institut de Recherche Pierre Fabre
    Full Title: A dose-finding study of efficacy and safety of F13640 in patients with moderate to severe painful peripheral diabetic polyneuropathy
    Medical condition: diabetic peripheral neuropathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012683 Diabetic peripheral neuropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) DE (Completed) HU (Completed) LT (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2022-000066-18 Sponsor Protocol Number: S65935 Start Date*: 2022-03-23
    Sponsor Name:Universitaire Ziekenhuizen Leuven
    Full Title: Metastasis-directed therapy for oligorecurrent prostate cancer: a randomized phase III trial
    Medical condition: Oligorecurrent hormone-sensitive prostate cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-004341-27 Sponsor Protocol Number: MK-3641-008 Start Date*: 2016-01-05
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia artemisiifolia) Sublingual Immunotherapy Tablet, in Children With a Histo...
    Medical condition: Rhinoconjunctivitis due to ragweed allergy
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) HR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003561-34 Sponsor Protocol Number: PCYC-1121-CA Start Date*: 2014-01-07
    Sponsor Name:Pharmacyclics LLC
    Full Title: A Multicenter, Open-Label, Phase 2 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Relapsed/Refractory Marginal Zone Lymphoma
    Medical condition: Relapsed or refractory marginal zone lymphoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004851 10029621 Non-Hodgkin's lymphomas unspecified histology indolent HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-010106-11 Sponsor Protocol Number: V72P16 Start Date*: 2009-06-26
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase 2 Observer-Blind Randomized Controlled Multicenter Dose-Ranging and Formulation-Finding Study of a new Novartis Meningococcal B Recombinant Vaccine evaluating the immunogenicity, tolerabili...
    Medical condition: The Novartis Meningococcal B Recombinant±OMV NZ vaccine is intended for prevention of meningitidis and/or septicemia caused by N.meningitidis serogroup B. This study is aimed at assessing the safe...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-004101-40 Sponsor Protocol Number: OS440-3005 Start Date*: 2018-03-23
    Sponsor Name:Osmotica Pharmaceutical US LLC
    Full Title: An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients with Spasticity (Study OS440-3005).
    Medical condition: Spasticity in patients with multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10041416 Spasticity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2006-000078-65 Sponsor Protocol Number: Rituximab Start Date*: 2007-01-17
    Sponsor Name:Karolinska University Hospital
    Full Title: Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
    Medical condition: Adult polymyositis or adult dermatomyositis or juvenile dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036102 Polymyositis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000436-28 Sponsor Protocol Number: Z102-008 Start Date*: 2011-12-07
    Sponsor Name:Zalicus, Inc.
    Full Title: A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, RANDOMIZED WITHDRAWAL DESIGN TRIAL USING ADAPTIVE RANDOMIZATION COMPARING Z102 WITH PLACEBO IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOI...
    Medical condition: Treatment of patients with moderate to severe rheumatoid arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) HU (Completed) BG (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 10 03:05:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA